HC Wainwright Trims Sol-Gel Technologies (NASDAQ:SLGL) Target Price to $6.00

Sol-Gel Technologies (NASDAQ:SLGL) had its price objective reduced by HC Wainwright from $9.00 to $6.00 in a research note published on Monday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Sol-Gel Technologies’ Q1 2024 earnings at ($0.16) EPS, Q2 2024 earnings at ($0.14) EPS, Q4 2024 earnings at ($0.17) EPS, Q1 2025 earnings at ($0.21) EPS, Q2 2025 earnings at ($0.21) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.10) EPS and FY2025 earnings at ($0.60) EPS.

Sol-Gel Technologies Stock Down 1.2 %

Shares of NASDAQ:SLGL opened at $0.79 on Monday. Sol-Gel Technologies has a fifty-two week low of $0.63 and a fifty-two week high of $4.05. The stock has a market cap of $22.01 million, a price-to-earnings ratio of -0.95 and a beta of 1.38. The firm’s 50 day moving average price is $0.88 and its 200 day moving average price is $1.10.

Sol-Gel Technologies (NASDAQ:SLGL) last released its quarterly earnings data on Wednesday, March 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.01). The firm had revenue of $0.45 million for the quarter, compared to analysts’ expectations of $0.27 million. Sol-Gel Technologies had a negative return on equity of 52.73% and a negative net margin of 1,329.13%. On average, equities analysts anticipate that Sol-Gel Technologies will post -0.67 EPS for the current year.

About Sol-Gel Technologies

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc, develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.